N-acylethanolamines (NAEs), which include the endocannabinoid anandamide, represent an important family of signaling lipids in the brain. The lack of chemical probes that modulate NAE biosynthesis in living systems hamper the understanding of the biological role of these lipids. Using a high-throughput screen, chemical proteomics and targeted lipidomics, we report here the discovery and characterization of LEI-401 as a CNS-active N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD) inhibitor. LEI-401 reduced NAE levels in neuroblastoma cells and in the brain of freely moving mice, but not in NAPE-PLD KO cells and mice, respectively. LEI-401 activated the hypothalamus–pituitary–adrenal axis and impaired fear extinction, thereby emulating the effect of a cannabinoid CB1 receptor antagonist, which could be reversed by a fatty acid amide hydrolase inhibitor. Our findings highlight the distinctive role of NAPE-PLD in NAE biosynthesis in the brain and suggest the presence of an endogenous NAE tone controlling emotional behavior.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
All data generated or analyzed during this study are included in this published article (and its Supplementary Information files) or are available from the corresponding author on reasonable request. The mass spectrometry proteomics data (raw data and ISOQuant output tables for proteins groups and peptides) have been deposited in the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE partner repository with the dataset identifier PXD017586.
Hannun, Y. A. & Obeid, L. M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 9, 139 (2008).
Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M. & Watanabe, M. Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev. 89, 309–380 (2009).
Alger, B. E. & Kim, J. Supply and demand for endocannabinoids. Trends Neurosci. 34, 304–315 (2011).
Piomelli, D. & Sasso, O. Peripheral gating of pain signals by endogenous lipid mediators. Nat. Neurosci. 17, 164 (2014).
Morena, M., Patel, S., Bains, J. S. & Hill, M. N. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology 41, 80 (2015).
Lutz, B., Marsicano, G., Maldonado, R. & Hillard, C. J. The endocannabinoid system in guarding against fear, anxiety and stress. Nat. Rev. Neurosci. 16, 705 (2015).
Pacher, P., Steffens, S., Haskó, G., Schindler, T. H. & Kunos, G. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat. Rev. Cardiol. 15, 151–166 (2018).
Maccarrone, M. Metabolism of the endocannabinoid anandamide: open questions after 25 years. Front. Mol. Neurosci. 10, https://doi.org/10.3389/fnmol.2017.00166 (2017).
Okamoto, Y., Morishita, J., Tsuboi, K., Tonai, T. & Ueda, N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem. 279, 5298–5305 (2004).
Hussain, Z., Uyama, T., Tsuboi, K. & Ueda, N. Mammalian enzymes responsible for the biosynthesis of N-acylethanolamines. Biochim. Biophys. Acta 1862, 1546–1561 (2017).
Magotti, P. et al. Structure of human N-acylphosphatidylethanolamine-hydrolyzing phospholipase D: regulation of fatty acid ethanolamide biosynthesis by bile acids. Structure 23, 598–604 (2015).
Wang, J. et al. Functional analysis of the purified anandamide-generating phospholipase D as a member of the metallo-β-lactamase family. J. Biol. Chem. 281, 12325–12335 (2006).
Leung, D., Saghatelian, A., Simon, G. M. & Cravatt, B. F. Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45, 4720–4726 (2006).
Tsuboi, K. et al. Enzymatic formation of N-acylethanolamines from N-acylethanolamine plasmalogen through N-acylphosphatidylethanolamine-hydrolyzing phospholipase D-dependent and -independent pathways. Biochim. Biophys. Acta 1811, 565–577 (2011).
Leishman, E., Mackie, K., Luquet, S. & Bradshaw, H. B. Lipidomics profile of a NAPE-PLD KO mouse provides evidence of a broader role of this enzyme in lipid metabolism in the brain. Biochim. Biophys. Acta 1861, 491–500 (2016).
Petersen, G., Pedersen, A. H., Pickering, D. S., Begtrup, M. & Hansen, H. S. Effect of synthetic and natural phospholipids on N-acylphosphatidylethanolamine-hydrolyzing phospholipase D activity. Chem. Phys. Lipids 162, 53–61 (2009).
Scott, S. A. et al. Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymes. ACS Chem. Biol. 10, 421–432 (2015).
Castellani, B. et al. Synthesis and characterization of the first inhibitor of N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD). Chem. Comm. 53, 12814–12817 (2017).
Karawajczyk, A., Orrling, K. M., de Vlieger, J. S. B., Rijnders, T. & Tzalis, D. The European Lead Factory: a blueprint for public–private partnerships in early drug discovery. Front. Med. 3, https://doi.org/10.3389/fmed.2016.00075 (2017).
Peppard, J.V., Mehdi, S., Li, Z. & Duguid, M.S. Assay methods for identifying agents that modify the activity of NAPE-PLD or ABH4. US patent WO2008150832A1 (2010).
Fu, J. et al. Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J. Biol. Chem. 282, 1518–1528 (2007).
Saghatelian, A., Jessani, N., Joseph, A., Humphrey, M. & Cravatt, B. F. Activity-based probes for the proteomic profiling of metalloproteases. Proc. Natl Acad. Sci. USA 101, 10000–10005 (2004).
van Rooden, E. J. et al. Mapping in vivo target interaction profiles of covalent inhibitors using chemical proteomics with label-free quantification. Nat. Protoc. 13, 752 (2018).
Lin, L. et al. Dietary fatty acids augment tissue levels of N-acylethanolamines in N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD) knockout mice. J. Nutr. Biochem. 62, 134–142 (2018).
Hill, M. N., Campolongo, P., Yehuda, R. & Patel, S. Integrating endocannabinoid signaling and cannabinoids into the biology and treatment of posttraumatic stress disorder. Neuropsychopharmacology 43, 80 (2017).
Locci, A. & Pinna, G. Stimulation of peroxisome proliferator-activated receptor-α by N-palmitoylethanolamine engages allopregnanolone biosynthesis to modulate emotional behavior. Biol. Psychiatry 85, 1036–1045 (2019).
Kathuria, S. et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9, 76 (2002).
Marsicano, G. et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418, 530–534 (2002).
Hill, M. N. et al. Endogenous cannabinoid signaling is essential for stress adaptation. Proc. Natl Acad. Sci. USA 107, 9406–9411 (2010).
Gunduz-Cinar, O. et al. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol. Psychiatry 18, 813–823 (2013).
Dincheva, I. et al. FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat. Commun. 6, 6395 (2015).
Morena, M. et al. Upregulation of anandamide hydrolysis in the basolateral complex of amygdala reduces fear memory expression and indices of stress and anxiety. J. Neurosci. 39, 1275–1292 (2019).
Zimmermann, T. et al. Impaired anandamide/palmitoylethanolamide signaling in hippocampal glutamatergic neurons alters synaptic plasticity, learning, and emotional responses. Neuropsychopharmacology 44, 1377–1388 (2018).
Hill, M. N. et al. Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic–pituitary–adrenal axis. Neuropsychopharmacology 34, 2733 (2009).
Bluett, R. J. et al. Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. Transl. Psychiatry 4, e408–e408 (2014).
Gray, J. M. et al. Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. J. Neurosci. 35, 3879 (2015).
Gunduz-Cinar, O., Hill, M. N., McEwen, B. S. & Holmes, A. Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol. Sci. 34, 637–644 (2013).
Tsuboi, K., Uyama, T., Okamoto, Y. & Ueda, N. Endocannabinoids and related N-acylethanolamines: biological activities and metabolism. Inflamm. Regen. 38, 28 (2018).
Ahn, K. et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem. Biol. 16, 411–420 (2009).
Fu, J. et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature 425, 90 (2003).
Solorzano, C. et al. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc. Natl Acad. Sci. USA 106, 20966–20971 (2009).
Cannich, A. et al. CB1 cannabinoid receptors modulate kinase and phosphatase activity during extinction of conditioned fear in mice. Learn. Mem. 11, 625–632 (2004).
Suzuki, A. et al. Memory reconsolidation and extinction have distinct temporal and biochemical signatures. J. Neurosci. 24, 4787 (2004).
Chhatwal, J. P. et al. Functional Interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning. Neuropsychopharmacology 34, 509–521 (2009).
Mayo, L. M. et al. Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase: a randomized, controlled experimental medicine trial. Biol. Psychiatry 87, 538–547 (2019).
Neumeister, A. et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol. Psychiatry 18, 1034–1040 (2013).
Geurts, L. et al. Adipose tissue NAPE-PLD controls fat mass development by altering the browning process and gut microbiota. Nat. Commun. 6, 6495 (2015).
Jourdan, T. et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat. Med. 19, 1132 (2013).
Hansen, H. H., Ikonomidou, C., Bittigau, P., Hansen, S. H. & Hansen, H. S. Accumulation of the anandamide precursor and other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death. J. Neurochem. 76, 39–46 (2001).
Sousa-Valente, J. et al. Inflammation of peripheral tissues and injury to peripheral nerves induce differing effects in the expression of the calcium-sensitive N-arachydonoylethanolamine-synthesizing enzyme and related molecules in rat primary sensory neurons. J. Comp. Neurol. 525, 1778–1796 (2017).
van der Wel, T. et al. A natural substrate-based fluorescence assay for inhibitor screening on diacylglycerol lipase α. J. Lipid Res. 56, 927–935 (2015).
Baggelaar, M. P. et al. Development of an activity-based probe and in silico design reveal highly selective inhibitors for diacylglycerol lipase-α in brain. Angew. Chem. Int. Ed. 52, 12081–12085 (2013).
Navia-Paldanius, D., Savinainen, J. R. & Laitinen, J. T. Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12). J. Lipid Res. 53, 2413–2424 (2012).
Soethoudt, M. et al. Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. Nat. Commun. 8, 13958 (2017).
van Esbroeck, A. C. M. et al. Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science 356, 1084–1087 (2017).
Council, N. R. Guide for the Care and Use of Laboratory Animals 8th edn (The National Academies Press, 2011).
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M. & Altman, D. G. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br. J. Pharmacol. 160, 1577–1579 (2010).
Cinar, R. et al. Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis. JCI Insight 1, e87336 (2016).
Mukhopadhyay, B. et al. Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver. Proc. Natl Acad. Sci. USA 108, 6323–6328 (2011).
The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115489, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (no. FP7/2007-2013) and EFPIA companies’ in kind contribution. M.v.d.S. was supported by a VICI-grant from the Netherlands Organization for Scientific Research and funding from Oncode Institute. Leiden University, Faculty of Science ‘Profiling Programme: Endocannabinoids’ is also acknowledged for financial support to E.D.M., V.K., T.H. and M.v.d.S. This research was also supported by National Institutes of Health National Institute on Drug Abuse (grant nos. R01DA039942 and P30DA0339340), Canadian Institutes of Health Research (grant no. FDN-143329 to M.N.H.) as well as start-up funds from the VCU School of Pharmacy to A.H.L. and the Intramural Research Program of NIAAA/NIH (to P.P., O.G.-C., L.I.C., C.M.D. and A.H.). We kindly acknowledge the Pharmaceutical Sciences division of F. Hoffman-La Roche Ltd for their technical assistance with the drug metabolism and pharmacokinetics experiments.
E.M., I.K. C.B. and M.v.d.S. are listed as inventors on patent application WO 2019/229250 A1 filed by Leiden University in which inhibitors of NAPE-PLD are disclosed.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Tables 1–7, Figs. 1–21 and Note.
Label-free quantification of mock- and hNAPE-PLD-FLAG transfected HEK293T cells treated with DMSO or LEI-401 (10 µM). Three biological replicates per condition. P values were calculated with a Student’s t-test (two-tailed, unpaired) and Benjamini–Hochberg correction (10% FDR).
About this article
Cite this article
Mock, E.D., Mustafa, M., Gunduz-Cinar, O. et al. Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice. Nat Chem Biol 16, 667–675 (2020). https://doi.org/10.1038/s41589-020-0528-7
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2021)
Structure–Activity Relationship Studies of Pyrimidine-4-Carboxamides as Inhibitors of N-Acylphosphatidylethanolamine Phospholipase D
Journal of Medicinal Chemistry (2021)
Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development
Journal of Medicinal Chemistry (2021)
Hit Discovery for Public Target Programs in the European Lead Factory: Experiences and Output from Assay Development and Ultra-High-Throughput Screening
SLAS DISCOVERY: Advancing the Science of Drug Discovery (2021)